Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Methocarbamol

×

Overview

What is Methocarbamol?

Methocarbamol Tablets, USP, a carbamate derivative of guaifenesin, are a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties. The structural formula is:

                 

The chemical name for Methocarbamol is 3-(2-Methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula CHNO. Its molecular weight is 241.24.

Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and -hexane.

Each tablet, for oral administration, contains 500 mg or 750 mg of methocarbamol, USP. In addition each tablet contains the following inactive ingredients: Colloidal Silicon Dioxide, Lactose Monohydrate, Magnesium Stearate, Methylcellulose, Microcrystalline Cellulose, Pregelatinized Starch and Sodium Starch Glycolate.



What does Methocarbamol look like?



What are the available doses of Methocarbamol?

Sorry No records found.

What should I talk to my health care provider before I take Methocarbamol?

Sorry No records found

How should I use Methocarbamol?

Methocarbamol Tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

500 mg – Adults:

750 mg – Adults:

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered.) Thereafter, the dosage can usually be reduced to approximately 4 grams a day.


What interacts with Methocarbamol?

Sorry No Records found


What are the warnings of Methocarbamol?

Sorry No Records found


What are the precautions of Methocarbamol?

Sorry No Records found


What are the side effects of Methocarbamol?

Sorry No records found


What should I look out for while using Methocarbamol?

Methocarbamol Tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol Tablets should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of Methocarbamol Tablets has not been established with regard to possible adverse effects upon fetal development.  There have been reports of fetal and congenital abnormalities following exposure to methocarbamol. Therefore, Methocarbamol Tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see ).


What might happen if I take too much Methocarbamol?

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.


How should I store and handle Methocarbamol?

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Protect from light.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Protect from light.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Protect from light.Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Methocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJWMethocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJWMethocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJWMethocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJWMethocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJWMethocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJWMethocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJWMethocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJWMethocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJWMethocarbamol Tablets 750 mg: White, Capsule Shaped, Scored Tablet; Debossed “West-ward 292”Blister of 30 tablets           NDC:67046-466-30 Store at 20-25C (68-77F) [See USP Controlled Room Temperature]. Protect from light and moisture.Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Manufactured by: Eatontown, NJ 07724Revised July 2009Repackaged by:Contract Pharmacy Services-PA Original--09/2009--NJWUpdated--08/2010--NJW


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

Non-Clinical Toxicology
Methocarbamol Tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol Tablets should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of Methocarbamol Tablets has not been established with regard to possible adverse effects upon fetal development.  There have been reports of fetal and congenital abnormalities following exposure to methocarbamol. Therefore, Methocarbamol Tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see ).

See and for interaction with CNS drugs and alcohol.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Adverse reactions reported coincident with the administration of methocarbamol include:

Body as a Whole

:

Car

d

iovascular System

:

Digestive System

:

Hemic and Lymphatic

S

ystem

:

  

Immune System

:

 

Nervous System

:

 

Skin and Special Senses

:

 

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).